Pasotuxizumab
Modify Date: 2024-01-04 13:32:20
Pasotuxizumab structure
|
Common Name | Pasotuxizumab | ||
|---|---|---|---|---|
| CAS Number | 1442657-12-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PasotuxizumabPasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2]. |
| Name | Pasotuxizumab |
|---|
| Description | Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2]. |
|---|---|
| Related Catalog | |
| Target |
KDs: 9.4 nM and 16.3 nM for human and cynomolgus monkey CD3. KDs: 47.0 nM and 212.6 nM for human and cynomolgus monkey PSMA. |
| In Vitro | Pasotuxizumab (约 0-100 ng/mL，48 小时) 可激活 CD4+ 和 CD8+ T 细胞群，EC50 为 3.4-6.7 ng/mL (人) 和 13.7-21.2 ng/mL (食蟹猴)[2]。 Pasotuxizumab (约 0-100 ng/mL，48 小时) 增加 T 细胞中干扰素-γ、TNF-α、IL-2 和 IL-10 的释放[2]。 |
| In Vivo | Rafivirumab (0.005-5 mg/kg，尾静脉注射，每日一次) 抑制 PC-3-huPSMA 小鼠异种移植模型中的肿瘤生长[2]。 Rafivirumab (0.1-1 mg/kg，静脉推注给药) 在 BALB/c 小鼠中表现出较低的血清清除率[2]。 Animal Model: PC-3-huPSMA mouse xenograft model[2] Dosage: 0.005-5 mg/kg Administration: i.v., once daily Result: Inhibited tumor growth by 86% (0.005 mg/kg/d) and 99% (5 mg/kg/d). Animal Model: BALB/c mice (PK Assay)[2] Dosage: 0.1, 0.3, and 1 mg/kg Administration: i.v. bolus administration or s.c. Result: Pharmacokinetic profile of Rafivirumab. Dose (mg/kg) AUC (mg h/L) CLmatrix (L/h/kg) T1/2 (h) F (%) i.v. (0.3) 0.93 0.32 9.7 100 s.c. (0.3) 0.17 11 18 |
| References |
| No Any Chemical & Physical Properties |